Literature DB >> 9468503

The N-terminal membrane domain of yeast NADPH-cytochrome P450 (CYP) oxidoreductase is not required for catalytic activity in sterol biosynthesis or in reconstitution of CYP activity.

K Venkateswarlu1, D C Lamb, D E Kelly, N J Manning, S L Kelly.   

Abstract

The disruption of Saccharomyces cerevisiae NADPH- cytochrome P450 oxidoreductase (CPR) gene resulted in a viable strain accumulating approximately 25% of the ergosterol observed in a sterol wild-type parent. The associated phenotypes could be reversed in transformants after expression of native CPR and a mutant lacking the N-terminal 33 amino acids, which localized in the cytosol. This indicated availability of the CPR in each case to function with the monooxygenases squalene epoxidase, CYP51, and CYP61 in the ergosterol biosynthesis pathway. Purification of the cytosolic mutant CPR indicated properties identical to native CPR and an ability to reconstitute ergosterol biosynthesis when added to a cell-free system, as well as to allow reconstitution of activity with purified CYP61, sterol 22-desaturase. This was also observed for purified Candida albicans and human CYP51 in reconstituted systems. The ability of the yeast enzyme to function in a soluble form differed from human CPR, which is shown to be inactive in reconstituting CYP activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468503     DOI: 10.1074/jbc.273.8.4492

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  S279 point mutations in Candida albicans Sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole.

Authors:  Andrew G S Warrilow; Jonathan G L Mullins; Claire M Hull; Josie E Parker; David C Lamb; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

2.  Dap1p, a heme-binding protein that regulates the cytochrome P450 protein Erg11p/Cyp51p in Saccharomyces cerevisiae.

Authors:  Julia C Mallory; Gerard Crudden; Ben L Johnson; Caiqing Mo; Charles A Pierson; Martin Bard; Rolf J Craven
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

3.  Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

Authors:  Andrew G S Warrilow; Claire M Martel; Josie E Parker; Nadja Melo; David C Lamb; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 4.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

Review 5.  Unusual properties of the cytochrome P450 superfamily.

Authors:  David C Lamb; Michael R Waterman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

6.  FMN binding site of yeast NADPH-cytochrome P450 reductase exposed at the surface is highly specific.

Authors:  Alexis S Ivanov; Oksana V Gnedenko; Andrey A Molnar; Alexander I Archakov; Larissa M Podust
Journal:  ACS Chem Biol       Date:  2010-08-20       Impact factor: 5.100

7.  Oxysterol-binding protein homologs mediate sterol transport from the endoplasmic reticulum to mitochondria in yeast.

Authors:  Siqi Tian; Akinori Ohta; Hiroyuki Horiuchi; Ryouichi Fukuda
Journal:  J Biol Chem       Date:  2018-02-27       Impact factor: 5.157

8.  Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae.

Authors:  Michael Fasullo; Autumn Smith; Patricia Egner; Cinzia Cera
Journal:  Mutat Res Genet Toxicol Environ Mutagen       Date:  2014-01-25       Impact factor: 2.873

9.  A functional heat shock protein 90 chaperone is essential for efficient flock house virus RNA polymerase synthesis in Drosophila cells.

Authors:  Kathryn M Castorena; Spencer A Weeks; Kenneth A Stapleford; Amy M Cadwallader; David J Miller
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

10.  The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.

Authors:  A G S Warrilow; C M Hull; J E Parker; E P Garvey; W J Hoekstra; W R Moore; R J Schotzinger; D E Kelly; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.